- Open Access
Correction to: Immunogenicity of adenovirus-vector vaccine targeting hepatitis B virus: non-clinical safety assessment in non-human primates
© The Author(s). 2018
- Received: 24 August 2018
- Accepted: 27 August 2018
- Published: 3 September 2018
The original article was published in Virology Journal 2018 15:111
Ad-HBV is a product (T101) aiming to treat chronic HBV firstly developed by Transgene S.A., France then by Transgene Tasly (Tianjin) Biopharmaceutical Co., Ltd., Tianjin, China in China. So, in the originally published article , the “Ad-HBV” appeared throughout the whole paper for 41 times should be replaced by “T101”.
Additionally, in the “Acknowledgements” section in the originally published article, “The Ad-HBV were a kind gift from Xia Meng (Transgene Tasly (Tianjin) Biopharmaceutical Co., Ltd., Tianjin, China). We want to thank Zhiming Wang and Xiaomin Wang (Transgene Tasly (Tianjin) Biopharmaceutical Co., Ltd., Tianjin, China) for teaching neutralization activity detection of anti-Ad antibodies” should be replaced by “We want to thank Transgene Tasly (Tianjin) Biopharmaceutical Co., Ltd., to provide us the opportunity to participate in the non-clinical safety assessment of T101, and most of the research work appeared in this paper came from the non-clinical safety assessment of T101”.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.